Business
Movement in share price
Movement in share price.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4505F Sareum Holdings PLC 28 July 2016 \n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nMovement in share price\nSareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes the movement in its share price on 27 July 2016. \nAn article was published by the Institute of Cancer Research (\"ICR\") in Molecular Cancer Therapeutics earlier this month, which came to Sareum's attention yesterday. The article refers to the evaluation of a Sareum/ICR developed CHK1 inhibitor, CCT244747, combined with radiotherapy in head and neck squamous cell carcinoma. Although the CHK1 inhibitor had beneficial effects, Sareum concluded, following consultation with its nominated adviser, that the information was not price sensitive as the ICR had previously published in 2013 on the benefits of a Sareum/ICR developed CHK1 inhibitor combined with radiotherapy, and as the CHK1 inhibitor used in the latest evaluation was not the CHK1 inhibitor, CCT245737, currently undergoing clinical trials co-funded by Sareum. \nFor further information:\n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n\n\n\n\n\nClaire Noyce / William Lynne\n\n\n020 3764 2341/2342\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n\n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\n \nNotes for editors: \nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. \nSareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes a programme in Phase I clinical trials and another undergoing pre-clinical IND-enabling studies. \nSKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 ...